Scribe Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Scribe Therapeutics's estimated annual revenue is currently $22M per year.
- Scribe Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Scribe Therapeutics has 142 Employees.
- Scribe Therapeutics grew their employee count by 28% last year.
Scribe Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder, President, and CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Co-Founder & Science Advisor | Reveal Email/Phone |
4 | Co-Founder and scientific advisor | Reveal Email/Phone |
5 | Co-founder and VP External Innovation | Reveal Email/Phone |
6 | VP Translational Sciences | Reveal Email/Phone |
7 | VP, Program Management | Reveal Email/Phone |
8 | Head Intellectual Property | Reveal Email/Phone |
9 | VP, Discovery Biology | Reveal Email/Phone |
10 | Controller | Reveal Email/Phone |
Scribe Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Scribe Therapeutics?
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
keywords:N/A
N/A
Total Funding
142
Number of Employees
$22M
Revenue (est)
28%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Scribe Therapeutics News
Benjamin Oakes. Co-founder and CEO, Scribe Therapeutics. Age: 33. Education: B.A. from Colby College; Ph.D. from UC Berkeley.
Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying...
Biotech firm Scribe Therapeutics appointed David Parrot as chief financial officer. Parrot joins the company from Barclays, where he was a...
Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisor ...
A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkeley genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed specifically to help develop and engineer new therapeutics based on CRISPR for addressi ...
Other Companies in Alameda
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27.8M | 150 | 8% | N/A |
#2 | $45.2M | 155 | 6% | N/A |
#3 | $24.3M | 157 | 69% | N/A |
#4 | $23M | 174 | 3% | N/A |
#5 | $39.7M | 176 | 2% | N/A |